Oncolytic viruses: overcoming translational challenges

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles

Targeted therapy of cancer using oncolytic viruses has generated much interest over the past few years in the light of the limited efficacy and side effects of standard cancer therapeutics for advanced disease. In 2006, the world witnessed the first government-approved oncolytic virus for the treatment of head and neck cancer. It has been known for many years that viruses have the ability to re...

Oncolytic Viruses

1Genelux Corporation, San Diego Science Center, San Diego, CA 92019, USA 2Department of Radiation Oncology, Rebecca and John Moores Comprehensive Cancer Center, University of California, San Diego, CA 92093, USA 3Department of Biochemistry, University of Wuerzburg, 97074 Wuerzburg, Germany 4Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, 97078 Wuerzburg, Germany 5 I...

Oncolytic viruses as immunotherapy: progress and remaining challenges

Oncolytic viruses (OVs) comprise an emerging cancer therapeutic modality whose activity involves both direct tumor cell lysis and the induction of immunogenic cell death (ICD). Cellular proteins released from the OV-lysed tumor cells, known as damage-associated molecular patterns and tumor-associated antigens, activate dendritic cells and elicit adaptive antitumor immunity. Interaction with the...

Cell carriers for oncolytic viruses: current challenges and future directions

The optimal route for clinical delivery of oncolytic viruses is thought to be systemic intravenous injection; however, the immune system is armed with several highly efficient mechanisms to remove pathogens from the circulatory system. To overcome the challenges faced in trying to delivery oncolytic viruses specifically to tumors via the bloodstream, carrier cells have been investigated to dete...

Overcoming the challenges of applying target enrichment for translational research